Clinical effects and kinetic properties of intravenous APSAC — anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarction
- 1 April 1986
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 11 (1), 53-61
- https://doi.org/10.1016/0167-5273(86)90199-3
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Intracoronary Thrombolytic Therapy Performed within a Coronary Care Unit: One Year's ExperienceScottish Medical Journal, 1985
- Intravenous administration of a thrombolytic agent is the only realistic therapeutic approach in evolving myocardial infarctionEuropean Heart Journal, 1985
- RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1985
- Systemic effects of BRL 26921 during thrombolytic treatment of acute myocardial infarctionThrombosis Research, 1985
- Coronary thrombolysis with intravenous anisoylated plasminogen-streptokinase complex BRL 26921.Heart, 1985
- Intracoronary streptokinase in acute evolving myocardial infarction: you can, but should you?International Journal of Cardiology, 1984
- Comparative prognostic value of radionuclide ventriculography at rest and during exercise in 100 patients after first myocardial infarction.Heart, 1983
- The effect of streptokinase on the fibrin binding site of plasmin(ogen)Thrombosis Research, 1981
- Prevalence of Total Coronary Occlusion during the Early Hours of Transmural Myocardial InfarctionNew England Journal of Medicine, 1980
- The fibrin plate method for estimating fibrinolytic activityArchives of Biochemistry and Biophysics, 1952